Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$5.28
NASDAQ
Change (%)
 Stock is Down 0.42 (7.37%)
Volume
390,868
02/10/16      4:00 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
02/03/16OvaScience to Present at Leerink Global Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 3, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 3:30 p.m. EST at the Waldorf Astoria New York in New York City. A live audio webcast of the presentat... 
Printer Friendly Version
01/11/16OvaScience Announces 2016 Corporate Goals for Its Core Fertility Treatments
- Company Will Webcast New Presentation at 34th Annual J.P. Morgan Healthcare Conference - WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new fertility treatment options, today announced its plans for 2016. OvaScience will present in a live webcast at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 14, 20... 
Printer Friendly Version
01/06/16OvaScience Names Harald F. Stock Chief Executive Officer-Elect
- Industry Veteran Brings Proven, Global Commercial Expertise – – Michelle Dipp Appointed Executive Chairman of the Board of Directors – WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced Harald F. Stock, Ph.D., will succeed Michelle Dipp, M.D., Ph.D. as CEO, effective July 1, 2016. Dr. Stock has nearly two decades of experience driving global comm... 
Printer Friendly Version
12/14/15OvaScience’s AUGMENT Fertility Treatment Available in Japan
- IVF JAPAN Begins Preceptorship Program with AUGMENT Treatment - WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 14, 2015-- OvaScienceSM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the AUGMENTSM fertility treatment is being offered in Japan through a preceptorship program at IVF JAPAN, one of the most prestigious fertility clinic systems in Japan... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources